SCHEMBL4473692

SCHEMBL4473692

Nc1nc(Nc2ccc(C(=O)O)cc2)sc1C(=O)c1ccccc1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNA2 P20248 13/20 0.85
CDK2 P24941 13/20 0.85
CDK5 Q00535 4/20 0.85
CDK5R1 Q15078 4/20 0.85
MAPT P10636 3/20 0.85
NPC1 O15118 3/20 0.85
RAB9A P51151 2/20 0.85
GSK3A P49840 1/20 0.85
GSK3B P49841 1/20 0.85
MAPK14 Q16539 1/20 0.85
TDP1 Q9NUW8 1/20 0.85
MEN1 O00255 4/20 0.72
KMT2A Q03164 4/20 0.72
LMNA P02545 1/20 0.72
CCNT1 O60563 1/20 0.65
CDK4 P11802 1/20 0.65
CCND1 P24385 1/20 0.65
CDK9 P50750 1/20 0.65
CDK6 Q00534 1/20 0.65
CDK11A Q9UQ88 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1248419 0.92 CCNA2 (1.00) CCNA2CDK2CDK5CDK5R1MAPT
SCHEMBL20142073 0.90 CCNA2 (0.68) CCNA2CDK2CDK5CDK5R1MAPT
SCHEMBL6192240 0.88 CCNA2 (0.82) CCNA2CDK2CDK5CDK5R1MAPT
SCHEMBL20142253 0.88 CCNA2 (0.82) CCNA2CDK2CDK5CDK5R1MAPT
SCHEMBL20142146 0.88 CCNA2 (0.90) CCNA2CDK2CDK5CDK5R1MAPT
SCHEMBL7757586 0.88 CCNA2 (0.82) CCNA2CDK2CDK5CDK5R1MAPT
SCHEMBL25609810 0.88 CCNA2 (0.82) CCNA2CDK2CDK5CDK5R1MAPT
SCHEMBL5724765 0.88 CCNA2 (0.87) CCNA2CDK2CDK5CDK5R1MAPT
SCHEMBL4489624 0.88 MEN1 (0.91) CCNA2CDK2CDK5CDK5R1MAPT
SCHEMBL20142350 0.88 MEN1 (0.91) CCNA2CDK2CDK5CDK5R1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 US disclosed
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 US disclosed
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 US disclosed
US-20060041006-A1 PDE4B inhibitors and uses therefor PLEXXIKON, INC. 2006-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PDE4B, PDE7B, PDE4A CCNA2 4015/4885CDK2 1537/4885CDK5 1039/4885
US-20060041006-A1 PDE4B inhibitors and uses therefor PDE4B, PDE7B, PDE4A CCNA2 4015/4885CDK2 1537/4885CDK5 1039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.